NCT07120503 - Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

October 31, 2027

Conditions

Asthma (Diagnosis)

Interventions

DRUG

WIN378

WIN378 is a fully human, long-acting monoclonal antibody that binds to thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving asthma control over an extended dosing interval.

DRUG

Placebo

A sham injection consisting of placebo to mask WIN378.

Trial Locations (5)

23226

NOT_YET_RECRUITING

WB Contracted Clinical Research Site, Richmond

29303

RECRUITING

WB Contracted Clinical Research Site, Spartanburg

33175

RECRUITING

WB Contracted Clinical Research Site, Miami

95117

NOT_YET_RECRUITING

WB Contracted Clinical Research Site, San Jose

90025-7014

NOT_YET_RECRUITING

WB Contracted Clinical Research Site, Los Angeles